Alto Neuroscience Inc (ANRO) Stock Price, Quote & News

Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 200 0412

Website: www.altoneuroscience.com

Address:

650 Castro Street, Suite 450, Mountain View, United States

ALRAE Sep. 5 at 11:48 AM

$ANRO

0 · Reply

DateNightMike Sep. 5 at 8:19 AM

$ANRO uhmmm what’s going on?

0 · Reply

Slayer69 Sep. 4 at 11:32 PM

$ANRO whoever is selling at $3.20, you suck! Hope you lost asshole!

0 · Reply

NVDAMillionaire Sep. 3 at 10:40 AM

$ANRO Brilliant piece that captures ANRO's situation perfectly. So if you want to update your understanding of ANRO or get to know ANRO better, this is essential reading. https://beyondspx.com/quote/ANRO/alto-neuroscience-unlocking-precision-psychiatry-with-biomarkers-and-a-deep-pipeline-nyse-anro#analysis

0 · Reply

BigSqueezeComing Sep. 2 at 8:58 PM

$ANRO https://www.newsfilecorp.com/release/264874/Shareholders-of-Alto-Neuroscience-Inc.-ANRO-Protect-Your-Rights-Before-September-19-2025-Contact-Levi-Korsinsky

0 · Reply

Moneywheel Aug. 29 at 3:14 PM

$ANRO it should respect that 3.57 USD gap by all means if we are in a bullish trend. Let's see how it unfolds from here .Not selling a single share.

0 · Reply

Ccperk Aug. 27 at 7:09 PM

$ANRO no one gives a flip about that class action lawsuit, investors are used to seeing these when the price goes down and 99% of the time goes nowhere

0 · Reply

DateNightMike Aug. 27 at 5:22 PM

$ANRO

0 · Reply

Stef_DL Aug. 26 at 7:28 PM

$ANRO I bought months ago at 3,6. I tought at that moment the bottom was reached. It has a been a long wait but it looks like the gap fill is finally coming up 😁.

0 · Reply

MOOSEN Aug. 26 at 7:08 PM

$ANRO TOTALLY MISSED THE BOAT.

1 · Reply

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 27, 2025, 2:17 PM EDT - 8 days ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Aug 27, 2025, 10:20 AM EDT - 8 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 22, 2025, 10:15 AM EDT - 13 days ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 18, 2025, 9:45 AM EDT - 18 days ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

Aug 18, 2025, 8:45 AM EDT - 18 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Aug 18, 2025, 8:03 AM EDT - 18 days ago

Alto Neuroscience to Participate in Upcoming Investor Conferences

Aug 13, 2025, 4:10 PM EDT - 22 days ago

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 13, 2025, 8:03 AM EDT - 23 days ago

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Aug 4, 2025, 2:46 PM EDT - 4 weeks ago

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

Jul 22, 2025, 6:25 PM EDT - 6 weeks ago

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jun 30, 2025, 8:03 AM EDT - 2 months ago

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Jun 26, 2025, 7:33 AM EDT - 2 months ago

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Jun 3, 2025, 6:03 AM EDT - 3 months ago

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

May 29, 2025, 8:03 AM EDT - 3 months ago

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

May 14, 2025, 4:10 PM EDT - 4 months ago

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 28, 2025, 8:03 AM EDT - 4 months ago

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Apr 22, 2025, 8:03 AM EDT - 4 months ago

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Mar 20, 2025, 4:10 PM EDT - 6 months ago

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

Mar 1, 2025, 11:00 AM EST - 6 months ago

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Feb 19, 2025, 8:03 AM EST - 7 months ago

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Feb 12, 2025, 8:03 AM EST - 7 months ago

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Feb 2, 2025, 11:00 AM EST - 7 months ago

The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud

Jan 27, 2025, 11:15 AM EST - 7 months ago

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Investigation Into Alto Neuroscience, Inc.

Jan 24, 2025, 1:15 PM EST - 7 months ago

The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Jan 22, 2025, 11:45 AM EST - 8 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Jan 3, 2025, 1:30 PM EST - 8 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience Inc For Securities Fraud

Dec 27, 2024, 12:15 PM EST - 8 months ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Alto Neuroscience Inc For Securities Fraud

ALRAE Sep. 5 at 11:48 AM

$ANRO

0 · Reply

DateNightMike Sep. 5 at 8:19 AM

$ANRO uhmmm what’s going on?

0 · Reply

Slayer69 Sep. 4 at 11:32 PM

$ANRO whoever is selling at $3.20, you suck! Hope you lost asshole!

0 · Reply

NVDAMillionaire Sep. 3 at 10:40 AM

0 · Reply

BigSqueezeComing Sep. 2 at 8:58 PM

$ANRO https://www.newsfilecorp.com/release/264874/Shareholders-of-Alto-Neuroscience-Inc.-ANRO-Protect-Your-Rights-Before-September-19-2025-Contact-Levi-Korsinsky

0 · Reply

Moneywheel Aug. 29 at 3:14 PM

$ANRO it should respect that 3.57 USD gap by all means if we are in a bullish trend. Let's see how it unfolds from here .Not selling a single share.

0 · Reply

Ccperk Aug. 27 at 7:09 PM

$ANRO no one gives a flip about that class action lawsuit, investors are used to seeing these when the price goes down and 99% of the time goes nowhere

0 · Reply

DateNightMike Aug. 27 at 5:22 PM

$ANRO

0 · Reply

Stef_DL Aug. 26 at 7:28 PM

$ANRO I bought months ago at 3,6. I tought at that moment the bottom was reached. It has a been a long wait but it looks like the gap fill is finally coming up 😁.

0 · Reply

MOOSEN Aug. 26 at 7:08 PM

$ANRO TOTALLY MISSED THE BOAT.

1 · Reply

BlackBerril Aug. 26 at 7:04 PM

$ANRO Now the pumpers arrive, lol. Hope you bought when I first issued the alert. And no, I don't have a scammy Discord to sell or a filthy YouTube channel to promote. Just a long-time trader trying to help my bros out.

1 · Reply

Moneywheel Aug. 26 at 7:02 PM

$ANRO if that 4,92$ goes…it could really run hard.

0 · Reply

Moneywheel Aug. 26 at 6:58 PM

$ANRO looking extremely good tech wise. Holding strong.

0 · Reply

BlackBerril Aug. 26 at 5:28 PM

$ANRO There is still time to jump on our gravy train. If you missed it earlier, no sweat. Pull back and look at the daily.

1 · Reply

Moneywheel Aug. 26 at 8:37 AM

$ANRO I have several clients who are really good at trading, being able to find the right EP and also TP, but they lack what to me after all these years trading the markets is the more important asset an outstanding trader must have: patience. If you have a strategy and you believe on your own skills…just stick to your initial plan and let time do the rest.

0 · Reply

Stef_DL Aug. 25 at 9:30 PM

$ANRO I'm long and glad to see that she's back at her highest point since March. A gap fill is getting near.

0 · Reply

BlackBerril Aug. 25 at 7:24 PM

$ANRO Why so quiet? Were people actually shorting? If so, I hope you get everything that's coming your way.

1 · Reply

RiskCaster Aug. 23 at 5:41 AM

$ANRO Alto Neuroscience is developing precision psychiatry treatments with novel biomarker approach

0 · Reply

Slayer69 Aug. 22 at 11:16 PM

$ANRO to whoever bought them 2 shares @ $3.97 at 6:35, you're my hero! Really surprised some dick hasn't sold into the bid yet. It's a great feeling that it's finally trading above my avg. Been a long wait since last year but will be well worth it. Good luck everyone and have a great evening. Go ANRO!

0 · Reply

XQuise Aug. 22 at 7:35 PM

$ANRO 💪🏻

0 · Reply

Drugtrade Aug. 22 at 6:00 PM

$ANRO did get to avg up a little yesterday.. look forward to positive update $10-20 target

0 · Reply

Moneywheel Aug. 22 at 5:18 PM

$ANRO 4,00$ on deck…glad for you guys…all you hold here!!!

0 · Reply

Market Cap	97.75M
Revenue (ttm)	0.00
Net Income (ttm)	-61.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.16

Volume	57,400
Avg Vol	181,098
Day's Range	N/A - N/A
Shares Out	27.08M
Stochastic %K	12%
Beta	1.91
Analysts	Strong Sell
Price Target	$10.33